Vaxcyte, Inc.
Vaxcyte, Inc. (PCVX): 21 pipeline candidates · 3 upcoming catalysts · ~18 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.0 months
D/E 0.12 · 0% dilution
Lead: Phase 3
21 candidates
3 upcoming, next in ~197d
0 buys · 14 sells (180d)
A transparent, data-derived signal for Vaxcyte, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.4B
Cash
$262.3M
Quarterly Burn
$280.6M
Runway
18.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (21 candidates)
| Drug | Phase |
|---|---|
| 0.5 ml dose of 1.1 mcg VAX-24 | Phase 2 |
| 0.5 ml dose of 2.2 mcg VAX-24 | Phase 2 |
| 0.5 ml dose of 2.2/4.4 mcg VAX-24 | Phase 2 |
| 0.5 mL dose of PCV20 | Phase 3 |
| 0.5 mL of the High-PFS dose VAX-31 | Phase 2 |
| 0.5 mL of the mid dose VAX-31 | Phase 2 |
| 20 valent pneumococcal conjugate vaccine | Phase 3 |
| 31 valent pneumococcal conjugate vaccine | Phase 3 |
| 31-valent pneumococcal conjugate vaccine | Phase 3 |
| PCV20 | Phase 3 |
Showing 10 of 21 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
335
Total value held
$9.82B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 33,151,750 | $1.92B |
| fmr llc | 16,492,861 | $958.4M |
| vanguard capital management llc | 12,533,402 | $728.3M |
| ra capital management, l.p. | 11,474,599 | $666.8M |
| blackrock, inc. | 10,971,816 | $637.6M |
| vanguard portfolio management llc | 6,279,545 | $364.9M |
| wellington management group llp | 5,614,597 | $326.3M |
| state street corp | 4,440,519 | $258.0M |
| deep track capital, lp | 4,300,000 | $249.9M |
| westfield capital management co lp | 3,646,138 | $211.9M |
Showing top 10 of 335 institutional holders of Vaxcyte, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vaxcyte, Inc.'s pipeline?
Vaxcyte, Inc. (PCVX) has 21 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vaxcyte, Inc.'s lead drug candidate?
Vaxcyte, Inc.'s most advanced tracked candidate is 0.5 ml dose of 1.1 mcg VAX-24 (Phase 2) for Pneumococcal Vaccines.
What is Vaxcyte, Inc.'s next catalyst?
Vaxcyte, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolera" — expected January 1, 2027.
What is Vaxcyte, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vaxcyte, Inc. has approximately 18.0 months of cash runway.
What is Vaxcyte, Inc.'s market capitalization?
Vaxcyte, Inc.'s market capitalization is approximately $7.4B.
Get the full picture on Vaxcyte, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.